Biocon plans to launch psoriasis drug novel biologic
The biotechnology firm plans to launch the drug in July 2013.
New Delhi, April 28, 2013: Biotechnology firm Biocon plans to launch its novel biologic drug Itolizumab branded as ‘Alzumab’ in the month of July 2013. It may be noted here that the drug will be used for the treatment of chronic plaque psoriasis in the country.
The drug will be manufactured at the Bengaluru-based Biopharma manufacturing facility of the company. The market for this drug is huge and the global market for psoriasis is estimated to cross US$ 8 billion by 2016.
The company also plans to extend the clinical development of the drug for the other auto-immune diseases. In fat, the company has also completed a pre-IND (Investigational New Drug) meeting for Itolizumab with the USFDA as the company plans for a global clinical development of the new medicine.